Evidence map›Paper›PMID 42034290›Full record

ArticleVirus research2026

Deuremidevir hydrobromide (VV116) is a promising antiviral against human metapneumovirus.

Huilong Wang, Haoli Yi, Tianwen Hu, Guanghui Tian, Yuanchao Xie, Wei Zheng, Jingshan Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huilong WangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Haoli YiSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Tianwen HuVigonvita Shanghai Co., Ltd., Shanghai, 201210, China.
Guanghui TianVigonvita Shanghai Co., Ltd., Shanghai, 201210, China.
Yuanchao XieState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Wei ZhengVigonvita Shanghai Co., Ltd., Shanghai, 201210, China. Electronic address: wei.zheng@vigonvita.cn.
Jingshan ShenState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. Electronic address: shenjingshan@simm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human metapneumovirus (hMPV) is a major respiratory pathogen for which no specific antiviral therapy is approved. In this study, we evaluated the anti-hMPV activity of the oral nucleoside analog VV116. In vitro, VV116 strongly inhibited hMPV replication in LLC-MK2 cells, with a half-maximal effective concentration (EC

Indexed as

Antiviral AgentsMetapneumovirusParamyxoviridae InfectionsAdenosineAnimalsCell LineDisease Models, AnimalHumansLungMiceViral LoadVirus ReplicationAdenosineAntiviral AgentsGS-621763Antiviral activityHuman metapneumovirusNucleos(t)ide analogVV116

Identifiers

PMID42034290
PMCPMC13137189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.